EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre‐emptive monitoring in the era of letermovir

Michelle K Yong iD, Monica A Slavin iD, Roy F Chemaly, Genovefa A Papanicolaou iD

Transplant Infectious Disease · 2023

DOI: 10.1111/tid.14171 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transplant Infectious Disease, 2023. Verfasst von Michelle K Yong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The preferred strategy for preventing CMV in at‐risk populations in alloHCT has undergone a significant practice shift in recent years where the pendulum has swung from a pre‐emptive approach to now offering letermovir prophylaxis to all CMV seropositive recipients. Letermovir prophylaxis has resulted in significant reductions in post‐transplant clinically significant CMV infection (csCMVi) as well as other important outcomes such as CMV disease, resistant, and refractory CMV infections and nonrelapse mortality. However, prophylactic strategies are not without some limitations, namely delayed onset CMV infections, delayed CMV‐specific T cell immune reconstitution, increased drug costs and limited data within pediatric populations. Thus, this review aims to provide an overview of prophylaxis and pre‐emptive CMV preventative strategies, and how they are applicable in the current era of letermovir prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsHematopoietic Stem Cell TransplantationChildHumansCytomegalovirusAntiviral AgentsAcetatesQuinazolines

Stichwörter der Autor:innen

allogeneic haematopoietic cell transplantationcytomegaloviruscytomegalovirus infectionprophylaxistransplantation

Substanzen

Antiviral AgentsletermovirAcetatesQuinazolines

Autor:innen und Institutionen

  • Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.
  • Department of Infectious Diseases, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Centre, Houston, Texas, USA.
  • Department of Medicine, Infectious Diseases Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Medicine, Weill Cornell Medical College, New York, New York, USA.

ORCID-Profile: Michelle K Yong, Monica A Slavin, Genovefa A Papanicolaou

Zitieren

APA

Yong, M. K., Slavin, M. A., Chemaly, R. F., & Papanicolaou, G. A. (2023). CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre‐emptive monitoring in the era of letermovir. Transplant Infectious Disease. https://doi.org/10.1111/tid.14171

Vancouver

Yong MK, Slavin MA, Chemaly RF, Papanicolaou GA. CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre‐emptive monitoring in the era of letermovir. Transplant Infectious Disease. 2023. doi:10.1111/tid.14171

BibTeX
@article{Yong2023,
  author = {Yong, Michelle K and Slavin, Monica A and Chemaly, Roy F and Papanicolaou, Genovefa A},
  title = {CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre‐emptive monitoring in the era of letermovir},
  journal = {Transplant Infectious Disease},
  year = {2023},
  doi = {10.1111/tid.14171}
}
Kostenlos starten →